Heron Therapeutics (HRTX) Operating Expenses (2010 - 2026)
Heron Therapeutics' (HRTX) quarterly Operating Expenses came in at $28.8 million in Q1 2026, up 5.66% YoY from $27.3 million in Q1 2025, and down 2.01% on a QoQ basis from $29.4 million in Q4 2025.
Heron Therapeutics (HRTX) Operating Expenses (2010 - 2026) Analysis & Trends
Heron Therapeutics (HRTX) has 17 years of Operating Expenses data on file, last reported at $28.8 million in Q1 2026.
- Quarterly Operating Expenses rose 5.66% year-over-year to $28.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $117.6 million (up 3.71% YoY) and the FY2025 annual result came in at $116.1 million, down 0.91% from the prior year.
- Operating Expenses slipped to $28.8 million in Q1 2026, from $29.4 million in the prior quarter.
- In the past five years, Operating Expenses ranged from a high of $86.4 million in Q1 2022 to a low of $26.4 million in Q4 2024.
- A 5-year average of $40.6 million and a median of $32.0 million in 2024 frame the typical range for Operating Expenses.
- The widest YoY moves for Operating Expenses: up 19.75% in 2022, down 49.11% in 2022.
- Tracing HRTX's Operating Expenses over 5 years: stood at $37.8 million in 2022, then retreated by 8.44% to $34.6 million in 2023, then dropped by 23.69% to $26.4 million in 2024, then advanced by 11.57% to $29.4 million in 2025, then slipped by 2.01% to $28.8 million in 2026.
- The last three Operating Expenses figures came in at $28.8 million (Q1 2026), $29.4 million (Q4 2025), and $30.4 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 2.89 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 960.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 1.21 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.06 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 427.03 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 541.02 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -784.57 Mn |
| 10 | Heron Therapeutics | 58.32 Mn | 15.65 Mn | 26.09 Mn | 28.14 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 28.14 Mn |
| Mar 31, 2026 | 28.84 Mn |
| Dec 31, 2025 | 29.43 Mn |
| Sep 30, 2025 | 30.39 Mn |
| Jun 30, 2025 | 28.98 Mn |
| Mar 31, 2025 | 27.29 Mn |
| Dec 31, 2024 | 26.38 Mn |
| Sep 30, 2024 | 27.81 Mn |
| Jun 30, 2024 | 31.95 Mn |
| Mar 31, 2024 | 31.02 Mn |
| Dec 31, 2023 | 34.57 Mn |
| Sep 30, 2023 | 38.16 Mn |
| Jun 30, 2023 | 54.01 Mn |
| Mar 31, 2023 | 45.82 Mn |
| Dec 31, 2022 | 37.76 Mn |
| Sep 30, 2022 | 53.72 Mn |
| Jun 30, 2022 | 77.13 Mn |
| Mar 31, 2022 | 86.38 Mn |
| Dec 31, 2021 | 74.19 Mn |
| Sep 30, 2021 | 74.94 Mn |